JP2004532638A - p53経路のモディファイヤーとしてのMAP3Ksおよび使用方法 - Google Patents

p53経路のモディファイヤーとしてのMAP3Ksおよび使用方法 Download PDF

Info

Publication number
JP2004532638A
JP2004532638A JP2003502009A JP2003502009A JP2004532638A JP 2004532638 A JP2004532638 A JP 2004532638A JP 2003502009 A JP2003502009 A JP 2003502009A JP 2003502009 A JP2003502009 A JP 2003502009A JP 2004532638 A JP2004532638 A JP 2004532638A
Authority
JP
Japan
Prior art keywords
mapk
assay
modulator
assay system
pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003502009A
Other languages
English (en)
Japanese (ja)
Inventor
フリードマン,ローリ
プラウマン,グレゴリー,ディー.
ベルビン,マーシャ
フランシス−ラング,ヘレン
リー,ダンクシー
フンケ,ロール,ピー.
Original Assignee
エクセリクシス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセリクシス・インコーポレイテッド filed Critical エクセリクシス・インコーポレイテッド
Publication of JP2004532638A publication Critical patent/JP2004532638A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4739Cyclin; Prad 1
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/988Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003502009A 2001-06-05 2002-06-03 p53経路のモディファイヤーとしてのMAP3Ksおよび使用方法 Withdrawn JP2004532638A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US32860501P 2001-10-10 2001-10-10
US35725302P 2002-02-15 2002-02-15
US36119602P 2002-03-01 2002-03-01
PCT/US2002/017457 WO2002098889A2 (fr) 2001-06-05 2002-06-03 Map3ks utiles en tant que modificateurs de la voie p53 et methodes d'utilisation

Publications (1)

Publication Number Publication Date
JP2004532638A true JP2004532638A (ja) 2004-10-28

Family

ID=27501675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003502009A Withdrawn JP2004532638A (ja) 2001-06-05 2002-06-03 p53経路のモディファイヤーとしてのMAP3Ksおよび使用方法
JP2003502178A Withdrawn JP2005514906A (ja) 2001-06-05 2002-06-03 p53経路のモディファイヤーとしてのLCEsおよび使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003502178A Withdrawn JP2005514906A (ja) 2001-06-05 2002-06-03 p53経路のモディファイヤーとしてのLCEsおよび使用方法

Country Status (5)

Country Link
EP (2) EP1402051A4 (fr)
JP (2) JP2004532638A (fr)
AU (1) AU2002314887A1 (fr)
CA (2) CA2448112A1 (fr)
WO (4) WO2002099068A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
DE10316701A1 (de) * 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
CA2532150A1 (fr) 2003-07-11 2005-01-20 Banyu Pharmaceutical Co., Ltd. Methode d'evaluation de compose efficace dans le traitement de l'obesite
EP1677739A4 (fr) * 2003-09-04 2008-07-23 Immusol Inc Methodes permettant d'identifier des agents qui inhibent la croissance des cellules cancereuses
WO2005083425A2 (fr) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Agents de diagnostic et de therapie destines aux maladies associees a la proteine kinase 13 activee par un mitogene (map3k13)
JP2008502151A (ja) 2004-06-04 2008-01-24 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 印刷可能半導体素子を製造して組み立てるための方法及びデバイス
CN105826345B (zh) 2007-01-17 2018-07-31 伊利诺伊大学评议会 通过基于印刷的组装制造的光学系统
EP2430652B1 (fr) 2009-05-12 2019-11-20 The Board of Trustees of the University of Illionis Ensembles imprimés de diodes électroluminescentes inorganiques microscopiques ultraminces pour dispositifs d'affichage déformables et semi-transparents
US9442285B2 (en) 2011-01-14 2016-09-13 The Board Of Trustees Of The University Of Illinois Optical component array having adjustable curvature
WO2012158709A1 (fr) 2011-05-16 2012-11-22 The Board Of Trustees Of The University Of Illinois Barrettes de del à gestion thermique assemblées par impression
EP2713863B1 (fr) 2011-06-03 2020-01-15 The Board of Trustees of the University of Illionis Réseau d'électrodes de surface conformables, multiplexées de manière active et à haute densité, pour un interfaçage avec le cerveau
US9691873B2 (en) 2011-12-01 2017-06-27 The Board Of Trustees Of The University Of Illinois Transient devices designed to undergo programmable transformations
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0572478T3 (da) * 1991-02-22 2006-01-16 Inst Medical W & E Hall HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5554523A (en) * 1994-03-01 1996-09-10 Children's Hospital Of Philadelphia Nucleic acid sequences encoding human leucine-zipper protein-kinase
AU3289599A (en) * 1998-02-13 1999-08-30 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
AU3354499A (en) * 1998-03-16 1999-10-11 Cadus Pharmaceutical Corporation Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
WO2000055330A1 (fr) * 1999-03-18 2000-09-21 The University Of Bristol Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans
CA2370195A1 (fr) * 1999-04-23 2000-11-02 Incyte Genomics, Inc. Proteines humaines associees aux membranes
WO2001007586A2 (fr) * 1999-07-22 2001-02-01 The University Of British Columbia Enzyme biosynthetique d'acides gras a chaines longues de plantes
JP2003520032A (ja) * 1999-11-12 2003-07-02 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 24個のヒト分泌タンパク質
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001270045A1 (en) * 2000-06-20 2002-01-02 Incyte Genomics, Inc. Secreted proteins
AU2001291745B2 (en) * 2000-08-11 2007-03-29 Merck Patent Gmbh Novel mitogen activated kinase
EP1341920A2 (fr) * 2000-11-29 2003-09-10 Xenon Genetics, Inc. Genes humains de l'elongase et leurs utilisations
JP2005504503A (ja) * 2001-02-06 2005-02-17 インサイト・ゲノミックス・インコーポレイテッド 受容体および膜関連タンパク質
WO2002062974A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine elongase hselo1
WO2002062975A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine du type elongase hselo1
WO2002096943A1 (fr) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Genes activant le stat6
AU2003231531A1 (en) * 2002-04-24 2003-11-10 Incyte Corporation Kinases and phosphatases

Also Published As

Publication number Publication date
WO2002098891A3 (fr) 2003-05-30
WO2002098889A2 (fr) 2002-12-12
EP1402262A4 (fr) 2005-05-11
CA2448112A1 (fr) 2002-12-12
CA2449479A1 (fr) 2002-12-12
AU2002314887A1 (en) 2002-12-16
WO2002099068A3 (fr) 2003-12-04
EP1402051A4 (fr) 2005-08-17
EP1402262A2 (fr) 2004-03-31
WO2002099068A2 (fr) 2002-12-12
WO2002098891A2 (fr) 2002-12-12
EP1402051A2 (fr) 2004-03-31
JP2005514906A (ja) 2005-05-26
WO2002098889A3 (fr) 2003-03-27
WO2002098468A1 (fr) 2002-12-12

Similar Documents

Publication Publication Date Title
US8153384B2 (en) Marks as modifiers of the p53 pathway and methods of use
US20050112568A1 (en) Dgks as modifiers of the p53 pathwha and methods of use
JP2004537321A (ja) p53経路のモディファイヤーとしてのHPRP4sおよび使用方法
JP2004532638A (ja) p53経路のモディファイヤーとしてのMAP3Ksおよび使用方法
JP2004534955A (ja) p21経路のモディファイヤーとしてのHADHsおよび使用方法
JP2004528045A (ja) p53経路のモディファイヤーとしてのP5CRsおよび使用方法
US8268548B2 (en) MAP3Ks as modifiers of the p53 pathway and methods of use
AU2002314883A1 (en) MAP3Ks as modifier of the p53 pathway and methods of use
AU2002312271A1 (en) MARKs as modifiers of the p53 pathway and methods of use
AU2002312284A1 (en) DGKS as modifiers of the p53 pathway and methods of use
AU2002312253A1 (en) LIMKs as modifiers of the p53 pathway and methods of use
AU2002310283A1 (en) PIBs as modifiers of the p53 pathway and methods of use
JP2007525964A (ja) p53経路のモディファイヤーとしてのSPPLsおよび使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050526

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070920